Is SLNO or FEMY more profitable?

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Soleno Therapeutics 33.70% 22.85% 18.25% Femasys -521.97% -258.08% -73.72%

Do analysts rate POCI or FEMY?

Femasys has a consensus target price of $106.67, suggesting a potential upside of 2,625.26%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Precision Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is POCI or FEMY more profitable?

Precision Optics has a net margin of -17.03% compared to Femasys' net margin of -521.97%. Precision Optics' return on equity of -37.47% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Precision Optics -17.03% -37.47% -19.96% Femasys -521.97% -258.08% -73.72%

Does the media prefer POCI or FEMY?

In the previous week, Femasys had 1 more articles in the media than Precision Optics. MarketBeat recorded 3 mentions for Femasys and 2 mentions for Precision Optics. Precision Optics' average media sentiment score of 0.94 beat Femasys' score of 0.22 indicating that Precision Optics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision Optics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, FEMY or MDAI?

Spectral AI has higher revenue and earnings than Femasys. Spectral AI is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.38M 4.97 -$18.63M -$5.40 N/A Spectral AI $19.65M 3.02 -$7.57M -$0.53 N/A

Is FEMY or MDAI more profitable?

Spectral AI has a net margin of -85.58% compared to Femasys' net margin of -521.97%. Spectral AI's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Spectral AI -85.58% N/A -72.97%

Does the media refer more to FEMY or MDAI?

In the previous week, Spectral AI had 1 more articles in the media than Femasys. MarketBeat recorded 4 mentions for Spectral AI and 3 mentions for Femasys. Spectral AI's average media sentiment score of 0.60 beat Femasys' score of 0.22 indicating that Spectral AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spectral AI 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FEMY or DXR?

Femasys presently has a consensus price target of $106.67, suggesting a potential upside of 2,625.26%. Given Femasys' higher probable upside, equities analysts plainly believe Femasys is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, FEMY or DXR?

Daxor has lower revenue, but higher earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.38M 4.97 -$18.63M -$5.40 N/A Daxor N/A N/A N/A N/A N/A

Is FEMY or DXR more profitable?

Daxor has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Daxor's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Daxor N/A N/A N/A

Do analysts rate QTEX or FEMY?

Femasys has a consensus target price of $106.67, indicating a potential upside of 2,625.26%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, QTEX or FEMY?

Inspira Technologies OXY B.H.N. has higher earnings, but lower revenue than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $290K 286.36 -$13.22M N/A N/A Femasys $2.38M 4.97 -$18.63M -$5.40 N/A

Does the media refer more to QTEX or FEMY?

In the previous week, Inspira Technologies OXY B.H.N. had 2 more articles in the media than Femasys. MarketBeat recorded 5 mentions for Inspira Technologies OXY B.H.N. and 3 mentions for Femasys. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.47 beat Femasys' score of 0.22 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Femasys (FEMY) Competitors

$3.91 -0.27 (-6.36%)

As of 12:47 PM Eastern

Compare

FEMY vs. SLNO, POCI, MDAI, DXR, and QTEX

Should you buy Femasys stock or one of its competitors? MarketBeat compares Femasys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Femasys include Soleno Therapeutics (SLNO), Precision Optics (POCI), Spectral AI (MDAI), Daxor (DXR), and Inspira Technologies OXY B.H.N. (QTEX). These companies are all part of the "medical equipment" industry.

How does Femasys compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Femasys	-521.97%	-258.08%	-73.72%

In the previous week, Femasys had 3 more articles in the media than Soleno Therapeutics. MarketBeat recorded 3 mentions for Femasys and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 beat Femasys' score of 0.22 indicating that Soleno Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Femasys	Neutral

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Femasys	$2.38M	4.97	-$18.63M	-$5.40	N/A

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Soleno Therapeutics currently has a consensus target price of $76.67, suggesting a potential upside of 44.63%. Femasys has a consensus target price of $106.67, suggesting a potential upside of 2,625.26%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Soleno Therapeutics has a beta of -2.22, suggesting that its share price is 322% less volatile than the broader market. Comparatively, Femasys has a beta of -2.23, suggesting that its share price is 323% less volatile than the broader market.

Summary

Soleno Therapeutics beats Femasys on 11 of the 15 factors compared between the two stocks.

How does Femasys compare to Precision Optics?

Precision Optics (NASDAQ:POCI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Femasys had 1 more articles in the media than Precision Optics. MarketBeat recorded 3 mentions for Femasys and 2 mentions for Precision Optics. Precision Optics' average media sentiment score of 0.94 beat Femasys' score of 0.22 indicating that Precision Optics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision Optics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precision Optics has a net margin of -17.03% compared to Femasys' net margin of -521.97%. Precision Optics' return on equity of -37.47% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision Optics	-17.03%	-37.47%	-19.96%
Femasys	-521.97%	-258.08%	-73.72%

Precision Optics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Femasys has a beta of -2.23, suggesting that its stock price is 323% less volatile than the broader market.

Femasys has a consensus target price of $106.67, suggesting a potential upside of 2,625.26%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

13.7% of Precision Optics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 14.4% of Precision Optics shares are owned by insiders. Comparatively, 7.6% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Precision Optics has higher revenue and earnings than Femasys. Precision Optics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision Optics	$28.94M	2.24	-$5.78M	-$0.63	N/A
Femasys	$2.38M	4.97	-$18.63M	-$5.40	N/A

Summary

Precision Optics beats Femasys on 9 of the 16 factors compared between the two stocks.

How does Femasys compare to Spectral AI?

Femasys (NASDAQ:FEMY) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Spectral AI had 1 more articles in the media than Femasys. MarketBeat recorded 4 mentions for Spectral AI and 3 mentions for Femasys. Spectral AI's average media sentiment score of 0.60 beat Femasys' score of 0.22 indicating that Spectral AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Femasys has a beta of -2.23, meaning that its share price is 323% less volatile than the broader market. Comparatively, Spectral AI has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Spectral AI has a net margin of -85.58% compared to Femasys' net margin of -521.97%. Spectral AI's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Spectral AI	-85.58%	N/A	-72.97%

Femasys presently has a consensus price target of $106.67, indicating a potential upside of 2,625.26%. Spectral AI has a consensus price target of $4.00, indicating a potential upside of 114.48%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spectral AI has higher revenue and earnings than Femasys. Spectral AI is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	4.97	-$18.63M	-$5.40	N/A
Spectral AI	$19.65M	3.02	-$7.57M	-$0.53	N/A

65.3% of Femasys shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 7.6% of Femasys shares are owned by company insiders. Comparatively, 13.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spectral AI beats Femasys on 11 of the 16 factors compared between the two stocks.

How does Femasys compare to Daxor?

Femasys (NASDAQ:FEMY) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Femasys presently has a consensus price target of $106.67, suggesting a potential upside of 2,625.26%. Given Femasys' higher probable upside, equities analysts plainly believe Femasys is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Femasys has a beta of -2.23, indicating that its share price is 323% less volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

In the previous week, Femasys had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for Femasys and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat Femasys' score of 0.22 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
Daxor	Very Positive

Daxor has lower revenue, but higher earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	4.97	-$18.63M	-$5.40	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

65.3% of Femasys shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 7.6% of Femasys shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Daxor's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Daxor	N/A	N/A	N/A

Summary

Daxor beats Femasys on 6 of the 11 factors compared between the two stocks.

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) and Femasys (NASDAQ:FEMY) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Femasys	-521.97%	-258.08%	-73.72%

Femasys has a consensus target price of $106.67, indicating a potential upside of 2,625.26%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Inspira Technologies OXY B.H.N. had 2 more articles in the media than Femasys. MarketBeat recorded 5 mentions for Inspira Technologies OXY B.H.N. and 3 mentions for Femasys. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.47 beat Femasys' score of 0.22 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inspira Technologies OXY B.H.N. has higher earnings, but lower revenue than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$290K	286.36	-$13.22M	N/A	N/A
Femasys	$2.38M	4.97	-$18.63M	-$5.40	N/A

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 7.6% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inspira Technologies OXY B.H.N. has a beta of 4.06, meaning that its share price is 306% more volatile than the broader market. Comparatively, Femasys has a beta of -2.23, meaning that its share price is 323% less volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Femasys on 9 of the 14 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.83M	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.73	20.08	24.01	24.71
Price / Sales	4.97	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.95	8.11	10.55	6.85
Net Income	-$18.63M	$23.89M	$3.56B	$337.45M
7 Day Performance	-27.38%	3.36%	1.54%	2.70%
1 Month Performance	-45.12%	1.34%	2.48%	4.60%
1 Year Performance	-77.99%	46.46%	26.49%	32.81%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	2.0663 of 5 stars	$3.91 -6.4%	$106.67 +2,625.3%	-76.5%	$11.83M	$2.38M	N/A	30	Analyst Upgrade Short Interest Increase Gap Up
SLNO Soleno Therapeutics	4.4169 of 5 stars	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
POCI Precision Optics	0.3822 of 5 stars	$5.62 flat	N/A	+26.1%	$61.51M	$28.94M	N/A	80
MDAI Spectral AI	2.3238 of 5 stars	$1.88 +1.4%	$4.00 +113.3%	-7.6%	$59.66M	$19.65M	N/A	83
DXR Daxor	3.3153 of 5 stars	$10.14 +0.4%	N/A	+13.6%	$59.22M	N/A	N/A	37

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. SLNO, POCI, MDAI, DXR, and QTEX

How does Femasys compare to Soleno Therapeutics?

Summary

How does Femasys compare to Precision Optics?

Summary

How does Femasys compare to Spectral AI?

Summary

How does Femasys compare to Daxor?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. SLNO, POCI, MDAI, DXR, and QTEX

How does Femasys compare to Soleno Therapeutics?

Is SLNO or FEMY more profitable?

Does the media refer more to SLNO or FEMY?

Which has better valuation and earnings, SLNO or FEMY?

Do insiders & institutionals hold more shares of SLNO or FEMY?

Do analysts recommend SLNO or FEMY?

Which has more risk & volatility, SLNO or FEMY?

Summary

How does Femasys compare to Precision Optics?

Does the media prefer POCI or FEMY?

Is POCI or FEMY more profitable?

Which has more risk & volatility, POCI or FEMY?

Do analysts rate POCI or FEMY?

Do insiders and institutionals hold more shares of POCI or FEMY?

Which has stronger valuation and earnings, POCI or FEMY?

Summary

How does Femasys compare to Spectral AI?

Does the media refer more to FEMY or MDAI?

Which has more risk & volatility, FEMY or MDAI?

Is FEMY or MDAI more profitable?

Do analysts recommend FEMY or MDAI?

Which has better earnings & valuation, FEMY or MDAI?

Do insiders & institutionals believe in FEMY or MDAI?

Summary

How does Femasys compare to Daxor?

Do analysts recommend FEMY or DXR?

Which has more risk and volatility, FEMY or DXR?

Does the media favor FEMY or DXR?

Which has stronger valuation & earnings, FEMY or DXR?

Do insiders and institutionals hold more shares of FEMY or DXR?

Is FEMY or DXR more profitable?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Is QTEX or FEMY more profitable?

Do analysts rate QTEX or FEMY?

Does the media refer more to QTEX or FEMY?

Which has preferable earnings and valuation, QTEX or FEMY?

Do institutionals & insiders believe in QTEX or FEMY?

Which has more volatility & risk, QTEX or FEMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools